Statements (45)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:healthcare_organization
|
| gptkbp:affects |
bone marrow
|
| gptkbp:associated_with |
risk of leukemia
|
| gptkbp:complications |
gptkb:healthcare_organization
thrombocytopenia bleeding disorders neutropenia |
| gptkbp:genetic_diversity |
T P53
ASX L1 DNM T3 A S F3 B1 TE T2 |
| https://www.w3.org/2000/01/rdf-schema#label |
myelodysplastic syndromes
|
| gptkbp:is_characterized_by |
ineffective hematopoiesis
|
| gptkbp:is_popular_in |
higher in older adults
|
| gptkbp:research_focus |
biomarkers
clinical trials genetic studies new therapies |
| gptkbp:risk_factor |
age
radiation exposure exposure to chemicals previous chemotherapy |
| gptkbp:scientific_classification |
gptkb:healthcare_organization
gptkb:chronic_myelomonocytic_leukemia refractory anemia |
| gptkbp:social_responsibility |
more common in men
bone marrow biopsy varies by subtype depends on age depends on overall health incidence increases with age depends on cytogenetics |
| gptkbp:symptoms |
gptkb:fandom
fatigue bleeding infections |
| gptkbp:treatment |
growth factors
supportive care chemotherapy immunosuppressive therapy bone marrow transplant hypomethylating agents |